HONG KONG, CHINA - Media OutReach - 24 November 2016 - ORI Healthcare Fund L.P. ("ORI Fund") announces that it has led a US$100 million Series-C investment in Kymab Group Limited (the "Company" or "Kymab"), a UK Cambridge-based company focusing on generating high-quality, fully humanized antibodies to treat challenging diseases based on the...
More...
